Denis Schallier

Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

Marleen Keyaerts, Catarina Xavier, Johannes Heemskerk et al. · Journal of Nuclear Medicine · 2015 · 435 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

Jacques De Grève, Erik Teugels, Caroline Geers et al. · Lung Cancer · 2012 · 277 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients

C. Collen, N. Christian, Denis Schallier et al. · Annals of Oncology · 2014 · 171 citations

Medicine, Oncology, Radiation Oncology +17

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

Jacques De Grève, Teresa Morán, Marie-Pascale Graas et al. · Lung Cancer · 2015 · 89 citations

Medicine, Oncology, Pharmacology +12

Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)

Lore Decoster, Denis Schallier, Hendrik Everaert et al. · Lung Cancer · 2008 · 67 citations

Medicine, Nuclear Medicine, Oncology +17